# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY

A. 510(k) Number: k090810   
B. Purpose for Submission: Clearance of a new device   
C. Measurand: CD3, CD4, CD8, CD16, CD56, CD19, CD45 Lymphocytes   
D. Type of Test: Quantitative and Semi-quantitative flow cytometric assay   
E. Applicant: Microgenics Corp.   
F. Proprietary and Established Names: Thermo Scientific Cyto-Cal™ Count Tubes   
G. Regulatory Information: 1. Regulation section: 864.5220; Differential Cell Counter 2. Classification: Class II 3. Product code: GKZ; Automated differential cell counter 4. Panel: Hematology (81)

# H. Intended Use:

1. Intended use(s): Thermo Scientific Cyto-Cal™ Count Tubes are used for determining absolute counts of leucocytes in blood. Thermo Scientific Cyto-Cal™ Count Tubes are used with the immunophenotyping reagents BD TriTEST™, flow cytometers BD FACS Calibur or BD FACS Canto, and software BD CellQuest or DIVA.   
2. Indication(s) for use: Same as Intended Use   
3. Special conditions for use statement(s): For Prescription Use Only   
4. Special instrument requirements: Thermo Scientific Cyto-Cal™ Count Tubes are for use with BD TriTEST™ reagent and the BD FACS Calibur or BD FACS Canto analyzers.

# I. Device Description:

Thermo Scientific Cyto-Cal™ Count Tubes contain uniform $5 . 4 \mathrm { u m }$ microspheres encapsulated with three proprietary oil soluble dyes. The single tube contains fluorescent beads that have equivalent emissions to multiple channels for FITC, PE, Per-CP, PE-Cy5, APC. Each tube contains a known number of fluorescent particles. Each pouch contains 25 tubes.

# J. Substantial Equivalence Information:

1. Predicate device name(s): BD Trucount Tubes   
2. Predicate K number(s): K965053   
3. Comparison with predicate:

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Thermo Scientific Cyto-CalrM Count Tubes</td><td rowspan=1 colspan=1>BD Trucount Tubes</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>Thermo Scientific Cyto-CalTM Count Tubesare used for determining absolute counts ofleucocytes in blood. Thermo Scientific Cyto-CalTM Count Tubes are used with theimmunophenotyping reagents BD TriTESTTM,flow cytometers BD FACS Calibur or BDFACS Canto, and software BD CellQuest orDIVA. Thermo Scientific Cyto-CalTM CountTubes can be used with the BD FACSTMLoader.</td><td rowspan=1 colspan=1>Used for determiningabsolute counts leucocytes inblood. BD Trucount Tubesare designed for use with invitro diagnostic productssuch as BD TriTest reagents,and a suitably equipped flowcytometer. BD TrucountTubes can be used with theBD FACS Loader.</td></tr><tr><td rowspan=1 colspan=1>Test Principle</td><td rowspan=1 colspan=1>Add the cell typing monoclonal antibodyreagent and whole blood directly to theThermo Scientific Cyto-CalTM Count Tubes.The dried pellet in the tube dissolves, releasinga known number of fluorescent beads. Duringanalysis, the absolute number (cells/μL) ofpositive cells in the sample can be determinedby comparing cellular events to bead events. Ifthe appropriate software, such as BDMultiSET, is used absolute counts will bedetermined by the software. If you aremanually performing data analysis usingsoftware such as BD CellQuest, divide thenumber of positive cellular events, thenmultiply by the Thermo Scientific Cyto-CalTM bead concentration.</td><td rowspan=1 colspan=1>Same (only with BDTrucount Tubes)</td></tr><tr><td rowspan=1 colspan=1>Matrix</td><td rowspan=1 colspan=1>Dried pellet of fluorescent beads in a single-use tube.</td><td rowspan=1 colspan=1>Freeze-dried pellet offluorescent beads in a single-use tube.</td></tr><tr><td rowspan=1 colspan=1>Instrument</td><td rowspan=1 colspan=1>Flow cytometer</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>StorageCondition</td><td rowspan=1 colspan=1>2 - 25C</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>ParticleConcentration</td><td rowspan=1 colspan=1>~ 50,000/tube</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Lysingreagent</td><td rowspan=1 colspan=1>FACS Lyse</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Supplied</td><td rowspan=1 colspan=1>Each pouch contains 25 tubes, sufficient for 25tests.</td><td rowspan=1 colspan=1>Same</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

Not applicable.

# L. Test Principle:

The test principle applies to immunophenotyping of lymphocytes. The cell typing monoclonal antibody reagent and whole blood are directly added to the Thermo

Scientific Cyto-Cal™ Count Tubes. The dried pellet in the tube dissolves, releasing a known number of fluorescent beads. During analysis, the absolute number $( \mathrm { c e l l s } / \mu \mathrm { L } )$ of positive cells in the sample can be determined by comparing cellular events to bead events. If the appropriate software, such as BD MultiSET, is used absolute counts will be determined by the software. If performing manual data analysis using software such as BD CellQuest, divide the number of positive cellular events, then multiply by the Thermo Scientific Cyto-Cal™ bead concentration.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility: Precision studies were performed to assess absolute count within-run reproducibility for low, normal, and high CD3 and CD3CD4 samples. For each sample, twenty-one (21) aliquots of whole blood were stained with CD3/CD4/CD45 TriTEST reagent using Thermo Scientific Cyto-Cal™ Count Tubes. The range of CVs for CD3 cells, observed for all samples were $4 . 0 \%$ - $6 . 2 \%$ . Acceptance Criteria: Medium and High Cell Concentration Samples - $\leq 5 \%$ CV, Low Cell Concentration Samples (Semi-quantitative with-in run) - $7 . 5 \%$ CV. The range of CD3CD4 cells, observed for all samples were $4 . 3 \%$ - $6 . 9 \%$ . Precision data met the acceptance criteria.

Within-run results:   

<table><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Subset</td><td rowspan=1 colspan=1>Mean cells/μL</td><td rowspan=1 colspan=1>CV%</td></tr><tr><td rowspan=2 colspan=1>Low</td><td rowspan=2 colspan=1>21</td><td rowspan=1 colspan=1>CD3+</td><td rowspan=1 colspan=1>549</td><td rowspan=1 colspan=1>6.2</td></tr><tr><td rowspan=1 colspan=1>CD3+CD4+</td><td rowspan=1 colspan=1>369</td><td rowspan=1 colspan=1>6.9</td></tr><tr><td rowspan=2 colspan=1>Medium</td><td rowspan=2 colspan=1>21</td><td rowspan=1 colspan=1>CD3+</td><td rowspan=1 colspan=1>1875</td><td rowspan=1 colspan=1>3.8</td></tr><tr><td rowspan=1 colspan=1>CD3+CD4+</td><td rowspan=1 colspan=1>1220</td><td rowspan=1 colspan=1>3.9</td></tr><tr><td rowspan=2 colspan=1>High</td><td rowspan=2 colspan=1>21</td><td rowspan=1 colspan=1>CD3+</td><td rowspan=1 colspan=1>3602</td><td rowspan=1 colspan=1>4.9</td></tr><tr><td rowspan=1 colspan=1>CD3+CD4+</td><td rowspan=1 colspan=1>1996</td><td rowspan=1 colspan=1>4.7</td></tr></table>

$b$ . Linearity/assay reportable range:

To assess linearity and recovery, a dilution recovery study was performed. One fresh whole blood sample was concentrated by removing plasma. This high sample was diluted with serum to $80 \%$ , $60 \%$ $40 \%$ , $20 \%$ and $0 \%$ . The results are as follows:

Expected results vs. measured values   

<table><tr><td rowspan=1 colspan=1>Subset</td><td rowspan=1 colspan=1>r</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>Intercept</td></tr><tr><td rowspan=1 colspan=1>CD3+</td><td rowspan=1 colspan=1>0.9996</td><td rowspan=1 colspan=1>0.991</td><td rowspan=1 colspan=1>17.492</td></tr><tr><td rowspan=1 colspan=1>CD3+CD4+</td><td rowspan=1 colspan=1>0.9990</td><td rowspan=1 colspan=1>1.0094</td><td rowspan=1 colspan=1>12.159</td></tr></table>

Recovery was within $10 \%$ of expected value for levels tested.

c. Traceability, Stability, Expected values (controls, calibrators, or methods): A reagent Shelf-Life Stability study was performed on three lots of CytoCal™ Count Tubes at room temperature $( 2 0 ^ { \circ } { - } 2 5 ^ { \circ } \mathrm { C } )$ . Bead counts were measured from Day 0 to 16 months and recovery was expected to be within $\pm 1 0 \%$ of Day 0 value for up to 16 months. Recovery was greater than $9 8 \%$ of Day 0 for all three lots for up to 16 months.

d. Detection limit:

Not applicable.

e. Analytical specificity:

An interference study was performed to determine the potential of endogenous and exogenous substances to affect accuracy. The interference was assessed by adding known amounts of interfering substances into whole blood with a $\mathrm { C D 4 + }$ concentration of $3 9 8 { \mathrm { ~ c e l l s } } / { \mu \mathrm { L } }$ . Acceptance Criteria: $\mathrm { C D 4 + }$ Count Measured recovers within $\pm 1 0 \%$ of $\mathrm { C D 4 } ^ { + }$ . No interference was observed for samples adjusted in the $\mathrm { p H }$ range of 6.8 – 8.8, in addition to sample conditions listed below:

EDTA: No significant interference from EDTA $1 0 ~ \mathrm { m g / m L }$ Icterus (jaundice): No significant interference from Bilirubin up to $2 0 \mathrm { m g / d L }$ Hemoglobin: No significant interference from Hemoglobin up to $2 0 \ \mathrm { g / d L }$ Lipemia: No significant interference from Triglycerides up to $5 0 0 \mathrm { m g / d L }$ Total Protein: No significant interference from Albumin up to $1 2 \ \mathrm { g / d L }$ Package insert lists other substances tested with specific concentrations. f. Assay cut-off: Not applicable.

2. Comparison studies:

a. Method comparison with predicate device: Method comparison studies were performed at one internal site (70 samples) and two external sites (40 samples). The results are as follows:

Internal Site   

<table><tr><td rowspan=1 colspan=1>Subset</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>r</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>Intercept</td></tr><tr><td rowspan=1 colspan=1>CD3+</td><td rowspan=1 colspan=1>70</td><td rowspan=1 colspan=1>0.9969</td><td rowspan=1 colspan=1>0.996</td><td rowspan=1 colspan=1>-0.3</td></tr><tr><td rowspan=1 colspan=1>CD4+</td><td rowspan=1 colspan=1>70</td><td rowspan=1 colspan=1>0.9956</td><td rowspan=1 colspan=1>0.995</td><td rowspan=1 colspan=1>-3.6</td></tr></table>

External Sites combined   

<table><tr><td rowspan=1 colspan=1>Subset</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>r</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>Intercept</td></tr><tr><td rowspan=1 colspan=1>CD3+</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>0.9769</td><td rowspan=1 colspan=1>0.967</td><td rowspan=1 colspan=1>-29.4</td></tr><tr><td rowspan=1 colspan=1>CD4+</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>0.9847</td><td rowspan=1 colspan=1>1.021</td><td rowspan=1 colspan=1>-29.1</td></tr><tr><td rowspan=1 colspan=1>CD8+</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>0.9646</td><td rowspan=1 colspan=1>0.911</td><td rowspan=1 colspan=1>-7.1</td></tr><tr><td rowspan=1 colspan=1>CD16+ CD56+</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0.9916</td><td rowspan=1 colspan=1>1.010</td><td rowspan=1 colspan=1>-7.7</td></tr><tr><td rowspan=1 colspan=1>CD19+</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0.9931</td><td rowspan=1 colspan=1>0.917</td><td rowspan=1 colspan=1>-0.36</td></tr><tr><td rowspan=1 colspan=1>CD4/8 ratio</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>0.9942</td><td rowspan=1 colspan=1>0.967</td><td rowspan=1 colspan=1>0.064</td></tr><tr><td rowspan=1 colspan=1>CD45+</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0.9812</td><td rowspan=1 colspan=1>1.016</td><td rowspan=1 colspan=1>-109.6</td></tr></table>

b. Matrix comparison: Not applicable.

3. Clinical studies:

a. Clinical Sensitivity: Not applicable.

$b$ . Clinical specificity: Not applicable.

c. Other clinical supportive data (when a. and b. are not applicable): Not applicable.

4. Clinical cut-off: Not applicable.

5. Expected values/Reference range: Reference ranges as published by the University of California, San Francisco: CD3 (T) Cells: 690 – 2540 cells $\mu \mathrm { L }$ CD4 (helper – inducer) T Cells: $4 1 0 - 1 5 9 0 \mathrm { c e l l s } / \mu \mathrm { L }$ CD8 (cytotoxic – suppressor) T Cells: 190 – 1140 cells/µL CD4/8 (H/S) Ratio: 0.8 – 4.2 CD19 (B) Cells: $9 0 - 6 6 0 \mathrm { c e l l s / \mu L }$ CD16, CD56 Natural Killer (NK) Cells: 90 – 590 cells/µL

N. Proposed Labeling: The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

O. Conclusion: The submitted information in this premarket notification is complete and supports a substantial equivalence decision.